PubRank

S I Rapaport

Author PubWeight™ 119.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980 4.02
2 Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977 2.79
3 The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969 2.61
4 Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984 2.26
5 Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990 1.90
6 Intravascular coagulation in fulminant meningococcemia. Ann Intern Med 1967 1.86
7 Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984 1.78
8 Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992 1.77
9 Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972 1.74
10 Studies of the activation of factor VII bound to tissue factor. Blood 1996 1.62
11 Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IX. Biochemistry 1970 1.62
12 Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990 1.57
13 Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood 1977 1.50
14 A plasma protein C activity assay suitable for a clinical laboratory. Its use to measure activity in hereditary and acquired deficiency states. Am J Clin Pathol 1987 1.44
15 Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med 1969 1.40
16 A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981 1.40
17 Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 1979 1.37
18 Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 1981 1.37
19 Hemophilia A: polymorphism detectable by a factor 8 antibody. Science 1969 1.32
20 Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988 1.22
21 Hemophilia B: characterization of genetic variants and detection of carriers. Blood 1977 1.20
22 Trousseau's syndrome. West J Med 1993 1.19
23 Defibrination after brain-tissue destruction: A serious complication of head injury. N Engl J Med 1974 1.17
24 Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970 1.16
25 Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin. Br J Haematol 1971 1.16
26 Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemost 1994 1.15
27 The blood clotting properties of rabbit peritoneal leukocytes in vitro. Thromb Diath Haemorrh 1967 1.15
28 Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci U S A 1988 1.15
29 Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985 1.13
30 Albinism and abnormal platelet function. N Engl J Med 1971 1.08
31 Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A 1991 1.07
32 Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979 1.07
33 Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987 1.05
34 Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979 1.04
35 The basalis of the primate endometrium: a bifunctional germinal compartment. Biol Reprod 1989 1.03
36 Endotoxin-induced intravascular clotting: the need for granulocytes. Thromb Diath Haemorrh 1968 1.02
37 Separation from Russell's viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry 1969 1.02
38 Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H- and 125I-labeled factor IX. Biochemistry 1983 0.99
39 A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation. J Biol Chem 1985 0.98
40 The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991 0.97
41 Consumption of serum factors and prothrombin during intravascular clotting in rabbits. Scand J Haematol 1966 0.97
42 A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983 0.96
43 Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem 1992 0.96
44 Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993 0.95
45 Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993 0.95
46 A procedure for isolation of human protein C and protein S as by-products of the purification of factors VII, IX, X and prothrombin. Prep Biochem 1983 0.95
47 Factor V anticoagulants: clinical, biochemical, and immunological observations. J Clin Invest 1970 0.94
48 Hemostatic factors in rabbit limb lymph: relationship to mechanisms regulating extravascular coagulation. Am J Physiol 1998 0.94
49 Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997 0.93
50 Thrombotic thrombocytopenic purpura. Serial clotting studies, relation to the generalized Shwartzman reaction, and remission after adrenal steroid and dextran therapy. Ann Intern Med 1967 0.93
51 Effects of thorium dioxide upon blood clotting and platelets. I. In vitro studies. Thromb Diath Haemorrh 1966 0.91
52 Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991 0.91
53 Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 1988 0.91
54 Activation of human factor VII by activated factors IX and X. Blood 1982 0.90
55 An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood 1974 0.89
56 Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986 0.89
57 The plasma protamine paracoagulation test: clinical and laboratory evaluation. Am J Clin Pathol 1972 0.87
58 Activation of 125I-factor IX and 125I-factor X: effect of tissue factor and factor VII, factor Xa and thrombin. Scand J Haematol 1980 0.87
59 Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994 0.87
60 Platelets and initiation of intrinsic clotting. Br J Haematol 1973 0.87
61 Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states. Am J Clin Pathol 1984 0.87
62 Further evidence that thrombin-activation of Factor 8 is an essential step in intrinsic clotting. Scand J Clin Lab Invest 1965 0.86
63 Intravascular clotting after endotoxin in rabbits with impaired intrinsic clotting produced by a factor VIII antibody. Blood 1973 0.86
64 Mechanism for diminished tissue factor expression by endothelial cells cultured with heparin binding growth factor-1 and heparin. Blood 1991 0.86
65 Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990 0.86
66 Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thromb Res 1978 0.85
67 Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989 0.85
68 Disappearance of fibrinogen-131-I after endotoxin: effects of a first and second injection. Am J Physiol 1968 0.84
69 Increased factor 8 levels in suspected carriers of hemophilia A taking contraceptives by mouth. N Engl J Med 1966 0.84
70 Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988 0.84
71 Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells. Thromb Haemost 1989 0.84
72 Activation of human factor VII during clotting in vitro. Blood 1985 0.84
73 Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemost 1989 0.83
74 Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 1990 0.83
75 Affinity purification of human brain tissue factor utilizing factor VII bound to immobilized anti-factor VII. Anal Biochem 1987 0.83
76 Effects of thorium dioxide upon blood clotting and platelets. II. In vivo studies in rabbits. Thromb Diath Haemorrh 1966 0.83
77 Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993 0.82
78 Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency. Blood 1976 0.82
79 Thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995 0.82
80 Immunologic characterization of 12 factor VIII inhibitors. Blood 1969 0.82
81 Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor. Thromb Haemost 1981 0.82
82 Preoperative hemostatic evaluation: which tests, if any? Blood 1983 0.82
83 Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. Arterioscler Thromb Vasc Biol 1995 0.81
84 The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994 0.81
85 Platelet aggregate ratios--standardization of technique and test results in patients with myocardial ischemia and patients with cerebrovascular disease. Thromb Haemost 1977 0.81
86 Failure of fibrinogen degradation products to increase plasma fibrinogen in rabbits. Proc Soc Exp Biol Med 1973 0.81
87 Cofactor of the "lupus anticoagulant". Thromb Diath Haemorrh 1974 0.81
88 Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. Blood 1985 0.80
89 Fibrinogen synthesis in adrenalectomized rabbits. Proc Soc Exp Biol Med 1973 0.80
90 A sensitive, accurate assay for extrinsic pathway inhibitor (EPI) activity in rabbit plasma: paradoxical effect of excess exogenous factor X. Thromb Res 1990 0.80
91 Decreased inducibility of tissue factor activity on human umbilical vein endothelial cells cultured with endothelial cell growth factor and heparin. Thromb Res 1988 0.80
92 Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996 0.80
93 Procoagulant activity of peritoneal leukocytes: effects of cortisone and endotoxin. Am J Physiol 1978 0.79
94 Evidence for an essential role of tissue factor dependent blood coagulation in the pathogenesis of the local Shwartzman reaction. Blood Cells Mol Dis 1995 0.79
95 Use of a generally applicable tissue factor--dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995 0.79
96 Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978 0.79
97 Effects of Thorotrast upon the reactivity and intravascular disappearance rate of fibrinogen in the rabbit. Proc Soc Exp Biol Med 1968 0.79
98 The mandatory role of lipid in the interaction of factors 8 and 9. Proc Soc Exp Biol Med 1966 0.79
99 A Protac-based screening test for activated protein C-resistant factor Va and other defects of the protein C anticoagulant pathway. Blood Coagul Fibrinolysis 1997 0.78
100 Evidence against collagen activation of platelet-associated factor XI as a mechanism for initiating intrinsic clotting. Scand J Haematol 1979 0.78
101 Heterogeneity in human prothrombin: analysis of cause. Blood 1981 0.78
102 The effects of injection of human factor VIII antibody into rabbits. Blood 1973 0.78
103 Hematologic effects of endotoxin on the macaque monkey. Surgery 1971 0.78
104 Rabbit factor V: different effects of thrombin and venom, a source of error in assay. Am J Physiol 1966 0.78
105 Increased fibrinogen consumption following endotoxin injection in cortisone-treated rabbits. Proc Soc Exp Biol Med 1974 0.77
106 Extra-adrenal effect of ACTH on fibrinogen synthesis. Am J Physiol 1973 0.77
107 Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 1973 0.77
108 Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody. Thromb Haemost 1994 0.77
109 Factor XI and platelets: Evidence that platelets contain only minimal factor XI activity and antigen. Br J Haematol 1977 0.76
110 Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). Thromb Res 1987 0.76
111 Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol 1986 0.76
112 Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb Haemost 1995 0.76
113 A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI). Thromb Res 1991 0.75
114 Editorial: Venous thrombosis--newer diagnostic and therapeutic approaches. West J Med 1974 0.75
115 Fibrinogen response to turpentine and endotoxin in busulfan-treated rabbbits. Thromb Haemost 1976 0.75
116 Systemic hemostatic failure in the severely injured patient. Surg Clin North Am 1968 0.75
117 A novel clotting assay for quantitation of plasma prothrombin (factor II) using Echis multisquamatus venom. Am J Clin Pathol 1999 0.75
118 Bleeding times and platelet aggregation after analgesics in hemophilia. Ann Intern Med 1972 0.75
119 Effects of endotoxin in cortisone-treated rabbits with a hereditary deficiency of the sixth component of complement (C6 deficiency). Thromb Haemost 1976 0.75
120 Patterns of incorporation of 75 Se-methionine into fibrinogen and other plasma proteins in rabbits stimulated by different test conditions. Thromb Diath Haemorrh 1973 0.75
121 Protac, a commercially available protein C activator from the venom of Agkistrodon contortrix contortrix, can activate factor V and factor VIII. Thromb Res 1997 0.75
122 The effect of platelets upon factor Xa-catalyzed activation of factor VII in vitro. Blood 1988 0.75
123 Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits. Thromb Haemost 1993 0.75
124 Fibrinogen levels after inflammation or endotoxin in normal and hypophysectomized rats. Am J Physiol 1975 0.75
125 Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency. Blood 1971 0.75
126 Failure of heparin, epsilon aminocaproic acid, or both agents to prevent increased fibrinogen levels after endotoxin in rabbits. Proc Soc Exp Biol Med 1973 0.75
127 Effect of corticosteroids upon fibrinogen metabolism in rabbits. Thromb Diath Haemorrh 1973 0.75
128 Studies of factor Xa/phospholipid-induced intravascular coagulation in rabbits. Effects of immunodepletion of tissue factor pathway inhibitor. Arterioscler Thromb 1993 0.75
129 Blood coagulation: biochemical, physiological and clinical considerations. Clin Obstet Gynecol 1968 0.75
130 Delayed incorporation of (75Se)selenomethionine into fibrinogen: its effect upon kinetic studies of fibrinogen with (75Se)selenomethionine in rabbits. Br J Haematol 1974 0.75
131 Cells and the activation of factor VII. Haemostasis 1996 0.75
132 Plasma PIVKA proteins in rabbits given warfarin. Thromb Res 1996 0.75
133 Research in medical schools--a personal view. West J Med 1974 0.75
134 The activation of factor IX by the tissue factor pathway. Prog Clin Biol Res 1981 0.75
135 Syndrome of an acquired inhibitor of factor VIII responsive to cyclophosphamide and prednisone. Ann Intern Med 1981 0.75
136 Reliability of a modified tissue factor-dependent factor V assay for activated protein C resistant factor Va using a calcium-containing thromboplastin. Thromb Haemost 1997 0.75
137 Failure to provoke the local Shwartzman reaction with thrombin. Proc Soc Exp Biol Med 1967 0.75
138 The effects of infusion of thrombin or endotoxin in rabbits treated with cortisone. Thromb Diath Haemorrh 1975 0.75
139 Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Blood 1989 0.75
140 Hemophilia polymorphism--the genetic plot thickens. N Engl J Med 1969 0.75
141 PTA (factor XI) levels after transfusion in patients with PTA deficiency. Bibl Haematol 1965 0.75
142 Hemostatic mechanisms in thrombogenesis: implications for therapy. Calif Med 1970 0.75